Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Clinical Study With MT-102 in Subjects With Cancer Cachexia

ABSTRACT: A phase II clinical study to evaluate MT-102 administered over a sixteen week period in subjects with cachexia related to non-small cell lung cancer and colorectal cancer

DISEASE(S): Cancer Cachexia,Cachexia,Wasting Syndrome,Cancer

PROVIDER: 2097861 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A multicentre, randomised, double-blind, placebo-controlled, dose-finding phase II study to evaluate the efficacy of two different doses of MT-102 administered over a sixteen week period in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer

Project description:Primary objectives: Demonstrate the effect of a 10mg/bd dose of MT-102 in comparison to placebo on the rate of weight change over a sixteen week period in patients with cachexia related to underlying stage III and stage IV colorectal or non-small cell lung cancer Primary endpoints: No primary end point

| 2528620 | ecrin-mdr-crc

A multicentre, randomised, double-blind, placebo-controlled, dose-finding phase II clinical study to evaluate the efficacy of two different doses of MT-102 administered over a sixteen week period in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer

Project description:Intervention1: MT-102: 1x 2.5mg tablet of MT-102 two times per day 1x 2.5mg tablet of MT-102 + 1 placebo tablet two times per day 1x 2.5mg tablet of MT-102 + 3 placebo tablet two times per day 1 x 2.5mg tablet of MT-102 two times per day 2x 2.5mg tablet of MT-102 two times per day 4 x 2.5mg tablets of MT-102 two times per day Control Intervention1: Placebo: 1x placebo tablet two times per day 2x placebo tablet two times per day 4x placebo tablet two times per day Primary outcome(s): Demonstrate the effect of a 10mg / bd dose of MT-102 in comparison to placebo on the rate of weight change over a sixteen week periodTimepoint: Day 7, 14, 21, 28, 56, 84, 112 and 140. Study Design: Randomized, Parallel Group, Placebo Controlled Trial Method of generating randomization sequence:Stratified randomization Method of allocation concealment:Centralized Blinding and masking:Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded

| 2572880 | ecrin-mdr-crc

RNA-seq of gastrocnemius muscle of orthotopic lung cancer mice with cachexia and sham control.

Project description:Cancer cachexia, highly prevalent in lung cancer, is a debilitating syndrome characterized by involuntary loss of skeletal muscle mass, and is associated with poor clinical outcome, decreased survival and negative impact on tumor therapy. Various lung tumor-bearing animal models have been used to explore underlying mechanisms of cancer cachexia. However, these models do not simulate anatomical and immunological features key to lung cancer and associated muscle wasting. Overcoming these shortcomings is essential to translate experimental findings into the clinic. We therefore evaluated whether a syngeneic, orthotopic lung cancer cachexia (OLCC) mouse model replicates systemic and muscle-specific alterations associated with human lung cancer cachexia. Immune competent, 11 weeks old male 129S2/Sv mice, were randomly allocated to either (1) sham control group or (2) tumor-bearing (OLCC) group. Syngeneic lung epithelium-derived adenocarcinoma cells (K-rasG12D; p53R172HΔG) were inoculated intrapulmonary into the left lung lobe of the mice. Body weight and food intake were measured daily. At baseline and weekly after surgery, grip strength was measured and tumor growth and muscle volume were assessed using micro cone beam CT imaging. After reaching predefined surrogate survival endpoint, animals were euthanized and skeletal muscles of the lower hind limbs were collected forRNA sequencing. RNA sequencing was performed on the Illumina NovasSeq 6000.

2023-04-03 | E-MTAB-12780 | biostudies-arrayexpress

Staphylococcus epidermidis strain:102 | isolate:102

Project description:Staphylococcus epidermidis strain:102 | isolate:102 Genome sequencing

| PRJNA1170200 | ENA

Skeletal muscle transcriptome profile in LLC mice model of cancer cachexia.

Project description:Cancer cachexia is a metabolic syndrome with alterations in gene expression profile that consequently lead to skeletal muscle wasting. Here, we used RNA sequencing to analyze the mRNA expression profile in the tibialis anterior muscles of the Lewis lung carcinoma (LLC) model of cancer cachexia.

2020-05-19 | GSE144567 | GEO

RNA-seq of vastus lateralis muscle biopsies of newly diagnosed treatment-naïve NSCLC patients with cachexia and age-matched and sex-matched healthy controls

2023-04-03 | E-MTAB-12781 | biostudies-arrayexpress

Endogenous small RNAs from Chlamydomonas reinhardtii strain J3(mt-) vegetative cells

Project description:endogenous small RNAs from Chlamydomonas reinhardtii strain J3(mt-) vegetative cells Keywords: High throughput 454 small RNA sequencing

2007-06-04 | GSE7575 | GEO

Skeletal muscle transcriptome profile in LLC mice model of cancer cachexia [miRNA-seq]

Project description:Cancer cachexia is a metabolic syndrome with alterations in gene expression profile that consequently lead to skeletal muscle wasting. Here, we used RNA sequencing to analyze the microRNA expression profile in the tibialis anterior muscles of the Lewis lung carcinoma (LLC) model of cancer cachexia.

2020-05-19 | GSE145393 | GEO

Exercise training reverses cancer cachexia-induced decrease in muscle COPS2/TRIP15/ALIEN

Project description:The mechanisms underlying exercise-induced effects in the skeletal muscle during cancer cachexia progression have not been fully described. Here, we tested the hypothesis that different exercise training protocols could attenuate metabolic impairment in a severe model of cancer cachexia. Moderate-intensity training (MIT) and high-intensity interval training (HIIT) improved running capacity and prolonged lifespan in tumor-bearing rats. HIIT also reduced oxidative stress and reestablished muscle contractile function. An unbiased proteomics screening revealed that COP9 signalosome complex subunit 2 (COPS2), also known as thyroid receptor interacting protein 15 (TRIP15) or ALIEN, is one of the most downregulated proteins at the early stage of cancer cachexia progression. HIIT restored COPS2/TRIP15/ALIEN protein expression to the control levels. Moreover, lung cancer patients with low endurance capacity had lower muscle COPS2/TRIP15/ALIEN protein content compared to age- and sex-matched control subjects. We further established an in vitro model of cancer-induced muscle wasting using tumor cells-conditioned media to explore the potential protective role of COPS2/TRIP15/ALIEN for myotubes homeostasis. This in vitro model indicate that tumor cells produce factors that directly affect myotube metabolism, but COPS2/TRIP15/ALIEN overexpression is not able to fully reestablish metabolic homeostasis and protein content in myotubes incubated with tumor cells-conditioned media. The current study provides new insight into the role of exercise training as a co-therapy for cancer cachexia and uncovers COPS2/TRIP15/ALIEN as a novel potential target for cancer cachexia.

2021-09-08 | PXD013226 | Pride

MT alignment

Project description:Alignement including 83 MT AA sequences and 2 reference sequences, rCRS and RSRS

| EGAD00010001574 | EGA